Relapsed/Refractory Patients:

Treatment Options


Individuals who relapse shortly following completion of initial therapy may no longer respond to the initial medications used. These individuals, as well as those who do not respond to initial therapy, are said to have refractory disease. As with the primary treatment of myeloma, recent advances in research have created more options for treating relapsed/refractory disease. These options include combinations using some or all of the following therapies:

Revlimid® (lenalidomide)
Velcade® (bortezomib) for Injection
Thalomid® (thalidomide)
Doxil® (doxorubicin HCI)
Kyprolis (carfilzomib) for Injection
Pomalyst® (Pomalidomide)

Experimental treatments in clinical trials are also options. You can learn about many of the options in clinical trials using the links below:

Zolinza® (vorinostat)
Panobinostat (LBH589)
Aplidin (plitidepsin)
Elotuzumab (HuLuc63)
Treanda® (bendamustine hydrochloride)
Marizomib (NPI-0052)
Ixazomib (MLN9708)

A full summary of all experimental treatments for relapsed/refractory and newly diagnosed disease can be viewed on this table.

Visit the MMRF Patient Navigator program to determine which clinical trial(s) may be most appropriate for you.

High-dose chemotherapy and stem cell transplant is also an option for patients at relapse. Learn more about stem cell transplant.